Voyager Therapeutics (VYGR) Assets Average (2015 - 2026)
Voyager Therapeutics (VYGR) posted Assets Average of $235.8 million for Q1 2026, down 12.76% sequentially from $270.3 million in Q4 2025, and down 36.81% YoY from $373.1 million in Q1 2025.
Voyager Therapeutics (VYGR) Assets Average (2015 - 2026) Analysis & Trends
Voyager Therapeutics has reported Assets Average for 12 years, with the latest figure at $235.8 million in Q1 2026.
- Quarterly Assets Average fell 36.81% year-over-year to $235.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $235.8 million (down 36.81% YoY) and the FY2025 annual result came in at $322.7 million, down 13.3% from the prior year.
- Assets Average declined to $235.8 million in Q1 2026 per VYGR's latest filing, from $270.3 million in the prior quarter.
- Over five years, Assets Average peaked at $452.9 million in Q2 2024 and troughed at $170.9 million in Q4 2022.
- A 5-year average of $305.9 million and a median of $305.2 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2026: Assets Average jumped 88.96% in 2023, then tumbled 36.81% in 2026.
- Over 5 years, Assets Average stood at $170.9 million in 2022, then soared by 88.96% to $323.0 million in 2023, then advanced by 26.81% to $409.5 million in 2024, then sank by 34.0% to $270.3 million in 2025, then decreased by 12.76% to $235.8 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $235.8 million, $270.3 million, and $305.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | 208.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 208.54 Mn |
| Mar 31, 2026 | 235.80 Mn |
| Dec 31, 2025 | 270.30 Mn |
| Sep 30, 2025 | 305.21 Mn |
| Jun 30, 2025 | 337.67 Mn |
| Mar 31, 2025 | 373.15 Mn |
| Dec 31, 2024 | 409.55 Mn |
| Sep 30, 2024 | 431.13 Mn |
| Jun 30, 2024 | 452.91 Mn |
| Mar 31, 2024 | 410.44 Mn |
| Dec 31, 2023 | 322.97 Mn |
| Sep 30, 2023 | 305.09 Mn |
| Jun 30, 2023 | 325.92 Mn |
| Mar 31, 2023 | 247.83 Mn |
| Dec 31, 2022 | 170.92 Mn |
| Sep 30, 2022 | 185.54 Mn |
| Jun 30, 2022 | 206.39 Mn |
| Mar 31, 2022 | 209.02 Mn |
| Dec 31, 2021 | 189.31 Mn |
| Sep 30, 2021 | 196.75 Mn |